Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 1Not yet recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Carcinoma, Hepatocellular 61Stomach Neoplasms 46Carcinoma, Non-Small-Cell Lung 37Colorectal Neoplasms 24Esophageal Squamous Cell Carcinoma 19Lung Neoplasms 12Rectal Neoplasms 11Nasopharyngeal Carcinoma 11Esophageal Neoplasms 11Neoplasms 8Squamous Cell Carcinoma of Head and Neck 7Pancreatic Neoplasms 7Neoplasm Metastasis 7Cholangiocarcinoma 6Uterine Cervical Neoplasms 5Small Cell Lung Carcinoma 5Liver Neoplasms 5Triple Negative Breast Neoplasms 4Recurrence 4Endometrial Neoplasms 4Colonic Neoplasms 4Carcinoma, Renal Cell 4Solid Tumor 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Extranodal NK-T-Cell 3Colorectal Cancer Metastatic 3Carcinoma 3Breast Neoplasms 3Advanced Solid Tumors 3Advanced Solid Tumor 3

Interventions

pembrolizumab 5Oxaliplatin 3Nivolumab 3sintilimab 2Leucovorin 2Immune Checkpoint Inhibitors 2Fluorouracil 2Capecitabine 2Bevacizumab 2vicriviroc 1trifluridine tipiracil drug combination 1spartalizumab 1relatlimab 1regorafenib 1epacadostat 1dabrafenib 1copanlisib 1binimetinib 1atezolizumab 1Tiragolumab 1Irinotecan 1Fulvestrant 1E7046 1Cetuximab 1Azacitidine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Spinocerebellar Degenerations × sintilimab × Clear all
NCT07506109 2026-04-07

A Phase II Study of Sintilimab Combined With Ipilimumab N01, Cetuximab and Dabrafenib in Patients With Microsatellite-Stable, BRAF V600E-Mutated Metastatic Colorectal Cancer

Tianjin Medical University Cancer Institute and Hospital

Phase 2 Recruiting
49 enrolled
Gastrointestinal

Spinocerebellar Degenerations, Colorectal Neoplasms

NCT06594692 2024-09-19

mRCAT-C

Sir Run Run Shaw Hospital

Phase 2 Not yet recruiting
140 enrolled
Gastrointestinal

Colonic Neoplasms, Spinocerebellar Degenerations

Data powered by HemOnc (CC BY 4.0) Colophon âš¡